Advanced in Hepatitis C

Dr. Gyongyi Szabo

Gastroenterology
330 Brookline Ave, 
Boston, MA 
Accepting New Patients
36 Years of Experience
Advanced in Hepatitis C
330 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gyongyi Szabo is a Gastroenterologist in Boston, Massachusetts. Dr. Szabo has been practicing medicine for over 36 years and is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Hepatitis, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Colonoscopy. Dr. Szabo is currently accepting new patients.

Her clinical research consists of co-authoring 258 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 34 articles and participated in 1 clinical trial in the study of Hepatitis C.

Specialties
Gastroenterology
Licenses
Internal Medicine in MA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO

Locations

330 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

257 Total Publications

Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Journal: Nature reviews. Gastroenterology & hepatology
Published: August 28, 2025
Similar Doctors
Distinguished in Hepatitis C
Dr. Thomas Sepe
Gastroenterology
Distinguished in Hepatitis C
Dr. Thomas Sepe
Gastroenterology

University Gastroenterology, LLC

33 Staniford St, 
Providence, RI 
 (39.9 miles away)
401-421-8800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Sepe is a Gastroenterologist in Providence, Rhode Island. Dr. Sepe is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Visceromegaly, Hepatitis C, Hepatitis, and Endoscopy.

Distinguished in Hepatitis C
Dr. Emily D. Bethea
Gastroenterology
Distinguished in Hepatitis C
Dr. Emily D. Bethea
Gastroenterology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Emily Bethea is a Gastroenterologist in Boston, Massachusetts. Dr. Bethea is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Hepatitis C, Hepatitis, Hepatic Cystic Hamartoma, Liver Transplant, and Endoscopy. Dr. Bethea is currently accepting new patients.

Distinguished in Hepatitis C
Dr. Lisa Bocelli
Gastroenterology
Distinguished in Hepatitis C
Dr. Lisa Bocelli
Gastroenterology

Umass Memorial Medical Group Inc

55 Lake Ave N, 
Worcester, MA 
 (33.7 miles away)
508-334-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lisa Bocelli is a Gastroenterologist in Worcester, Massachusetts. Dr. Bocelli is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Chronic Pancreatitis, Childhood Pancreatitis, Hepatitis C, and Hereditary Pancreatitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Szabo's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile